Neurocrine Biosciences (NBIX) Shares Outstanding (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Shares Outstanding (Entity) for 17 consecutive years, with $101.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 2.63% year-over-year to $101.6 million; the trailing twelve-month figure through Jun 2026 stood at $101.6 million (up 2.63% YoY), and the FY2025 full-year result was $100.1 million, up 0.7% from the prior year.
• Shares Outstanding (Entity) rose to $101.6 million in Q2 2026 per NBIX's latest filing, from $100.6 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $101.6 million in Q2 2026 and bottomed at $95.5 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $98.8 million across 5 years, with a median of $99.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) rose 3.38% in 2024, then declined 1.88% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $96.5 million in 2022, then grew by 2.28% to $98.7 million in 2023, then advanced by 0.71% to $99.4 million in 2024, then grew by 0.7% to $100.1 million in 2025, then rose by 1.5% to $101.6 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $101.6 million, $100.6 million, and $100.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.